Platelet Reactivity and Stent Thrombosis: Still Some Issues to Solve  by Perez de Prado, Armando et al.
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August 11, 2009:661–8y frozen end-diastolic angiographic frames) otherwise frequently
eglected in a conventionally executed map. We adopted this
echnique as we previously observed that, in many cases, electro-
natomic maps failed to reflect RV angiographic shape and
imensions, in particular not depicting the true anatomical RV
pex. In this regard, the criticism of the fluoroscopic images in our
tudy appears completely inappropriate as the mapping catheter
nd the bioptome introducer clearly point to the free wall, well
bove the apex. In fact, Figure 1 illustrates the same patient as in
igure 2, in which the site of biopsy is clearly indicated in panel
D. In addition, in our study, the biopsy site was always visualized
hrough contrast medium flashes so that the execution of biopsies
ith both electroanatomic and angiographic guide further in-
reased the accuracy and the safety of the procedure. On the
ontrary, it remains unclear how Drs. Avella and d’Amati, in the
bsence of both cardiac MRI and angiography, presume to identify
the border zone” and “the thinner core” of the RV wall solely on
he basis of electroanatomic map. The identification of a low-
oltage area, conventionally defined as “scar,” cannot provide any
nformation on the thickness, and mostly on the histological
ubstrate of the wall segment. Moreover, like delayed enhancement
t cardiac MRI reflects an interstitial expansion whatever the cause
fibrosis, necrosis, edema, or amyloid deposition), different histo-
ogical substrates (fibrofatty replacement, fibrosis, necrosis, edema,
nd inflammatory infiltrates) can determine the presence of low-
oltage areas in different myocardial disorders.
As far as it concerns the absence of myocarditis in EMB from
ow-voltage areas in their study, this finding may “seem logical”
hen starting from the wrong assumption that “myocarditis is
nlikely to produce solid transmural scars detectable as low-voltage
reas with endocardial electroanatomic mapping.” In fact, it is well
stablished by experimental and clinical studies that myocarditis
ay produce transmural lesions at cardiac MRI and even inflam-
atory or post-inflammatory ventricular aneurysms (3,4), so that it
eems obvious that these alterations of ventricular structure and
unction may represent the substrate of electroanatomical abnor-
alities and mostly of repetitive ventricular arrhythmias.
Accordingly, abnormal electroanatomic maps in patients with
yocarditis as well as some cases of sarcoidosis mimicking ARVC
lectroanatomic features have already been reported (5,6). It is thus
ntriguing that Avella and coworkers failed to find patients with
yocarditis, either with normal or pathological electroanatomic map,
s this figure was reported in 50% of cases in both our and the
orrado et al. (7) series, probably denoting a bias in their patients’
election or EMB interpretation. In this regard, it should be empha-
ized that the Dallas criteria cited by Drs. Avella and d’Amati are no
onger considered sufficient, even in recent EMB guidelines (8,9), to
stablish the diagnosis of inflammatory cardiomyopathy, as immuno-
istochemistry is considered essential and polymerase chain reaction
or cardiotropic viruses relevant to define the inflammatory and viral
tiology, respectively, of cardiac lesions. Accordingly, in their hands,
he analysis of EMB from low-voltage areas, exclusively confirming
he diagnosis of ARVC and being nondiagnostic in 20% of cases,
ailed to add any diagnostic contribution to the sole execution of
lectroanatomic map. These findings may be misleading and, as
reviously suggested, may result from potential methodological biases.
Therefore, we can correctly state, as we did, that our study is the
rst to demonstrate that electroanatomic mapping-guided EMB
ay allow to modify the initial diagnosis and mostly the treatment
nd prognosis of patients with noninvasive diagnosis of ARVC. tMaurizio Pieroni, MD, PhD
rancesca Marzo, MD
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latelet Reactivity
nd Stent Thrombosis:
till Some Issues to Solve
e read with great interest the recent article by Sibbing et al. (1).
hey concluded that low response to clopidogrel assessed with
ultiple electrode platelet aggregometry (MEA) is significantly
ssociated with an increased risk of stent thrombosis. Considering
he potential clinical implications of this attractive study, address-
ng some methodological issues would be appreciated.
The authors remark that the platelet aggregation measurements
ere not normally distributed, suggesting a right-skewed curve of
he observed values. Different studies with smaller populations
han the current one have shown a normal distribution of the
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August 11, 2009:661–8latelet aggregation parameters with light transmission aggregom-
try (2,3) and point-of-care, VerifyNow P2Y12 assay (Accumet-
ics, San Diego, California) (4). In a previous publication (5), the
uthors demonstrated a good correlation between MEA and light
ransmission aggregometry results. Do the obtained values in that
opulation fit a normal distribution? Can any distinctive method-
logical characteristics of the MEA system explain this finding?
Another intriguing observation, conflicting with the published
vidence (6), is the significantly higher proportion of active
mokers in the group of low (upper quintile) responders to
lopidogrel. We should expect a higher rate of active smokers
mong patients presenting with acute myocardial infarction, which
as also related to lower response in the current study. It would be
ery interesting to know the individual influence of these variables
y performing a multivariate analysis considering lower response to
lopidogrel as the dependent variable.
Stent thrombosis (ST) is probably the most feared complication
fter percutaneous coronary intervention, irrespective of the time
f appearance. Early ST (acute and subacute) still occurs despite
he aggressive use of antiplatelet agents. Apart from adherence to
he antiplatelet treatment and platelet aggregation response, some
actors have been correlated with ST (7): lower left ventricle
jection fraction, smaller diameter of the reference vessel, longer
tent lengths, and lower final pressure to implant the stents. The
uthors of the present study (1) focus the statistical analysis on the
elations of different demographic, clinical, and procedural vari-
bles with the platelet aggregation values obtained with MEA.
owever, no data about the relationship between those variables
nd ST is provided. Do the previously published or any other
ariables correlate with ST? It sounds plausible that procedural and
ngiographic variables may play an important role in the develop-
ent of ST, especially in the case of early ST. A Cox proportional
azards model that includes the above-mentioned variables could
e very helpful to detect all the independent predictors of ST.
We absolutely agree with the authors that low response to
lopidogrel (or high post-treatment platelet reactivity) may iden-
ify patients at higher risk of stent thrombosis. But all the
echanisms and related factors should be clarified to better
revent ischemic cardiac events.
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eply
e appreciate the comments made by Dr. Perez de Prado and
olleagues concerning our recent article (1).
The observation of normally distributed platelet aggregation
PA) values is only an in vitro phenomenon depending on the
opulation studied and the method applied. Indeed, PA measure-
ents were not normally distributed in our study population (1),
nd in a previous study (2) we undertook with multiple electrode
latelet aggregometry (MEA) on the Multiplate analyzer
Dynabyte GmbH, Munich, Germany). This is in contrast to
bservations made with light transmission aggregometry (LTA)
nd the VerifyNow P2Y12 assay (Accumetrics, San Diego, Cali-
ornia). In MEA, adhesion and PA leads to an increased imped-
nce signal; the more platelets that adhere to the electrode, the
igher the impedance. Hence, MEA measurements have no
nherent upper limit, and this is likely to explain not normally
istributed PA data with MEA.
In fact, the observation of a higher proportion of active smokers
n the group of clopidogrel low responders (1) is in contrast to a
ecently published study using LTA and finding lower PA values
n active smokers compared with nonsmokers (3). For LTA, it
ust be kept in mind that platelet-rich plasma is an artificial
ilieu lacking erythrocytes, leukocytes, and larger platelet subspe-
ies, all of which influence the amount of PA (4). The link of
moking and leukocytosis is well known, and also the interaction of
eukocytes and platelets in atherothrombotic processes has been
stablished (5). Endothelial dysfunctions and platelet hyper-
eactivity have been well described in smokers, as well as a negative
ffect of smoking on the pharmacokinetics of clopidogrel (6). In
ight of this conflicting data, the issue of smoking and clopidogrel
esponse warrants further investigations, which we are currently
ndertaking in separate studies.
Concerning predictors of stent thrombosis (ST), we are aware
hat other variables apart from the ones included in our primary
nalysis may play a role in this setting. ST is a very rare event, and
comprehensive analysis on its predictors requires thousands of
atients. This was beyond the scope of our study, which was
esigned to assess the relationship of MEA measurements and ST.
s requested, however, by Dr. Perez de Prado and colleagues, we
xpanded the multivariable analysis by adding the suggested
ariables (ejection fraction [already included], vessel diameter, total
